Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Future Growth Of Spine Industry “At Risk,” Investor Panel Says

This article was originally published in The Gray Sheet

Executive Summary

The spinal industry that has produced robust growth over the past decade is “at risk,” according to an investor panel held at this month's annual meeting of the North American Spine Society in Orlando.

You may also be interested in...



Top Device Stories of 2010: A Look Back and a Glance Forward

This article was adapted from "Top Device Stories of 2010: Waiting for the Other Shoes to Fall," in the January 2011 issue of IN VIVO.

Top Device Stories of 2010: A Look Back and a Glance Forward

This article was adapted from "Top Device Stories of 2010: Waiting for the Other Shoes to Fall," in the January 2011 issue of IN VIVO.

Top Device Stories Of 2010: Waiting For The Other Shoes To Fall

For much of the device industry, 2010 felt like a transition year, breeding uncertainty in a number of important areas, including the economy, health care reform, and impending changes to the 510(k) process. A review of the year just ended turns up these stories: Device M&A on the Rebound; Is A First-Mover Advantage Emerging In Medtech? Boston Scientific Is Back In The Game; Early-Stage Deals In Decline; The Future Of Medtech: Where Private Investment Dollars Are Flowing; Transcatheter Valves Take Center Stage; Spine's Downturn; Diabetes Assumptions Begin To Shift; A Landmark Year In Ophthalmology; Health Reform In 2010: A Beginning, Not An End; Changes At FDA: 510(k) Reform Takes Shape, and finally, Is Physician Choice In Product Selection In Danger?

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT029523

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel